BioSig Technologies Inc.
| NASDAQ: BSGM |
| Healthcare / Medical Devices & Instruments / USA |
| 3.44 | -0.0600 | -1.71% | Vol 146.52K | 1Y Perf -57.48% |
| Jul 27th, 2021 14:50 DELAYED |
| BID | 3.42 | ASK | 3.45 | ||
| Open | 3.59 | Previous Close | 3.50 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 12.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 263.37 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/-33/87 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | 100/-99/-44 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/-98/-31 | Income Ranking | — - | |
| Market Cap | 110.70M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 9.31 | Earnings Date | 5th Aug 2021 |
Today's Price Range 3.333.59 | 52W Range 2.799.77 | 5 Year PE Ratio Range -3.20-3.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.31% | ||
| 1 Month | -2.78% | ||
| 3 Months | -7.16% | ||
| 6 Months | -20.45% | ||
| 1 Year | -57.48% | ||
| 3 Years | -38.60% | ||
| 5 Years | 0.36% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 4.70K | |||
ROE last 12 Months | -279.77 | |||
ROA (5Y Avg) | -70.40 | |||
ROA last 12 Months | -230.75 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -272.00 | |||
Return on invested Capital Q | -36.38 | |||
Return on invested Capital Y | -436.74 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.20 | ||||
| 6.46 | ||||
| - | ||||
| - | ||||
| -6.60 | ||||
| -0.93 | ||||
| 6.57 | ||||
| 0.57 | ||||
| 106.31M | ||||
| Forward PE | -7.40 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.60 | ||||
| 6.80 | ||||
| 0.00 | ||||
| 0.01 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | - | -0.38 | - |
| Q02 2020 | - | -0.72 | - |
| Q01 2020 | -0.25 | -0.46 | -84.00 |
| Q03 2019 | - | -0.25 | - |
| Q02 2019 | - | -0.38 | - |
| Q01 2018 | - | -0.22 | - |
| Q02 2017 | - | -0.30 | - |
| Q01 2017 | - | -0.35 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2020 QR | -0.24 | 0.00 | - |
| 9/2020 QR | -0.23 | 0.00 | - |
| 12/2020 FY | -1.17 | -408.70 | Negative |
| 12/2021 FY | -0.50 | 0.00 | - |
| Next Report Date | 5th Aug 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 146.52K |
| Shares Outstanding | 32.18M |
| Trades Count | 843 |
| Dollar Volume | 1.51M |
| Avg. Volume | 332.73K |
| Avg. Weekly Volume | 364.64K |
| Avg. Monthly Volume | 455.86K |
| Avg. Quarterly Volume | 353.55K |
BioSig Technologies Inc. (NASDAQ: BSGM) stock closed at 3.5 per share at the end of the most recent trading day (a -5.41% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 110.70M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 53 people. BioSig Technologies Inc. CEO is Kenneth L. Londoner.
The one-year performance of BioSig Technologies Inc. stock is -57.48%, while year-to-date (YTD) performance is -10.26%. BSGM stock has a five-year performance of 0.36%. Its 52-week range is between 2.79 and 9.77, which gives BSGM stock a 52-week price range ratio of 9.31%
BioSig Technologies Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 6.46, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -230.75%, a ROC of -272.00% and a ROE of -279.77%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BioSig Technologies Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BioSig Technologies Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for BioSig Technologies Inc. is Strong Buy (1), with a target price of $12.5, which is +263.37% compared to the current price. The earnings rating for BioSig Technologies Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioSig Technologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioSig Technologies Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.50, ATR14 : 0.32, CCI20 : -43.56, Chaikin Money Flow : -0.16, MACD : -0.04, Money Flow Index : 21.98, ROC : -8.85, RSI : 44.01, STOCH (14,3) : 24.69, STOCH RSI : 0.25, UO : 40.04, Williams %R : -75.31), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioSig Technologies Inc. in the last 12-months were: Kenneth L. Londoner (Buy at a value of $192 028), Martha Pease (Option Excercise at a value of $0), Odonnell F Jeffrey (Sold 105 000 shares of value $530 371 ), Samuel E. Navarro (Option Excercise at a value of $0), Steven Chaussy (Buy at a value of $12 079)
BioSig Technologies Inc.
BioSig Technologies Inc is a medical technology company. The firm is commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. Its first product, PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The company's subsidiary is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19.
CEO: Kenneth L. Londoner
Telephone: +1 203 409-5444
Address: 54 Wilton Road, Westport 06880, CT, US
Number of employees: 53
